In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Hypoxia, a condition characterized by reduced oxygen availability, has been widely studied for its potential therapeutic ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from $51.00 to $53.00 in a research note issued to investors on ...

Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 7.1% ...

After hours: February 4 at 4:25:05 PM EST Loading Chart for AGIO ...

Kathy describes sleeping at the bottom of the garden as a nightly ‘mini holiday’ because away from the house they can let go ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...